Update on risk-stratified management for chronic lymphocytic leukemia

References

• Zent C S, Kyasa M J, Evans R, Schichman S A. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001; 92: 1325–1330
   PubMed Web of Science ®Google Scholar
• Morton L M, Wang S S, Devesa S S, Hartge P, Weisenburger D D, Linet M S. Lymphoma incidence patterns by WHO subtype in the United States, 1992 – 2001. Blood 2006; 107: 265–276
   PubMed Web of Science ®Google Scholar
• Call T G, Phyliky R L, Noel P, Habermann T M, Beard C M, O'Fallon W M, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 323–328
   PubMed Web of Science ®Google Scholar
• Muller-Hermelink H K, Catovsky D, Montserrat E, Harris N L. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Tumours of haematopoietic and lymphoid tissues, E Jaffe, N Harris, H Stein, J Vardiman. IARC Press, Lyon 2001; 127–130
   Google Scholar
• Dighiero G, Binet J- L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1799–1801
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Geyer S M, Kay N E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202–1210
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Nowakowski G S, Dewald G W, Hoyer J D, Paternoster S F, Stockero K J, Fink S R, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005; 130: 36–42
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Dewald G W, Brockman S R, Paternoster S F, Bone N D, O'Fallon J R, Allmer C, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287–295
   PubMed Web of Science ®Google Scholar
• Zent C S, Kay N E. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep 2004; 6: 348–354
   PubMedGoogle Scholar
• Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506–1514
   PubMed Web of Science ®Google Scholar
• CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91: 861–868
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Fink S, Witzig T E, Paternoster S F, Smoley S, Stockero K, et al. Frequency of clonal evolution by FISH in untreated, early stage patients with CLL: a prospective, longitudinal study with long clinical follow-up. Blood 2005; 106: 2098, abstract
   Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–205
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T, Davis Z, Gardiner A, Oscier D, Stevenson F. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Jelinek D F, Tschumper R C, Geyer S M, Bone N D, Dewald G W, Hanson C A, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854–861
   PubMed Web of Science ®Google Scholar
• Oscier D G, Gardiner A C, Mould S J, Glide S, Davis Z A, Ibbotson R E, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101: 4952–4957
   PubMed Web of Science ®Google Scholar
• Thorselius M, Krober A, Murray F, Thunberg U, Tobin G, Buhler A, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-utilizing chronic lymphocytic leukemia independent of geographical origin and mutational status. Blood 2005, (Epub ahead of print)
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006, (Epub ahead of print)
   PubMed Web of Science ®Google Scholar
• Mauerer K, Zahrieh D, Gorgun G, Li A, Zhou J, Ansen S, et al. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol 2005; 129: 499–510
   PubMed Web of Science ®Google Scholar
• Widhopf G F, Kipps T J. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol 2001; 166: 95–102
   PubMed Web of Science ®Google Scholar
• Messmer B T, Albesiano E, Efremov D G, Ghiotto F, Allen S L, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200: 519–525
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher M R, Kofler D M, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742–751
   PubMed Web of Science ®Google Scholar
• Calin G A, Dumitru C D, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529
   PubMed Web of Science ®Google Scholar
• Cuneo A, Rigolin G M, Bigoni R, De Angeli C, Veronese A, Cavazzini F, et al. Chronic lymphocytic leukemia with 6q – shows distinct hematological features and intermediate prognosis. Leukemia 2004; 18: 476–483
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James M R, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516–2522
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, Rassenti L, Rai K, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614
   PubMed Web of Science ®Google Scholar
• Nolz J C, Tschumper R C, Pittner B T, Darce J R, Kay N E, Jelinek D F. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005; 19: 1018–1024
   PubMed Web of Science ®Google Scholar
• Castro J E, Prada C E, Loria O, Kamal A, Chen L, Burrows F J, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90)-client protein: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis and impaired signaling in chronic lymphocytic leukemia. Blood 2005; 106: 2506–2512
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146–2155
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do K A, O'Brien S, Huh Y O, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181–186
   PubMed Web of Science ®Google Scholar
• Lee Y K, Bone N D, Strege A K, Shanafelt T D, Jelinek D F, Kay N E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788–794
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Lee Y K, Call T G, Nowakowski G S, Dingli D, Zent C S, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2005, (Epub ahead of print)
   Web of Science ®Google Scholar
• Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• Byrd J C, Rai K, Peterson B L, Appelbaum F R, Morrison V A, Kolitz J E, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53
   PubMed Web of Science ®Google Scholar
• Kay N E, Lin T, Call T, Jelinek D F, Bone N D, Dewald G W, et al. Pentostatin combination therapy for untreated B-chronic lymphocytic leukemia. Blood 2003; 102: 676a
   Web of Science ®Google Scholar
• Keating M. Do we have the tools to cure CLL?. Hematology 2003; 165–169
   PubMedGoogle Scholar
• Keating M J, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078
   PubMed Web of Science ®Google Scholar
• Gribben J G. Salvage therapy for CLL and the role of stem cell transplantation. Hematology 2005; 292–298
   PubMedGoogle Scholar
• Faderl S, Thomas D A, O'Brien S, Garcia-Manero G, Kantarjian H M, Giles F J, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413–3415
   PubMed Web of Science ®Google Scholar
• Byrd J C, Peterson B L, Gabrilove J, Odenike O M, Grever M R, Rai K, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11: 4176–4181
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, DiMiceli L, Padmanabhan S, Lawrence D, Bernstein Z P, et al. Antileukemic effects of lenalidomide (Revlimid) in patients with relapsed or refractory chronic lymphocytic leukemia: results of a pilot phase II study. Leuk Lymphoma 2005; 46(Suppl. 1)S96–S97
   Google Scholar
• Coffier B, Tilly H, Pedersen L M, Plesner T, Frederiksen H, Van Oers M H, et al. A novel, fully human, anti-CD20 monoclonal antibody. First results from an ongoing phase I/II trial in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46(Suppl. 1)S96–S97
   Google Scholar
• Caballero D, Garcia-Marco J A, Martino R, Mateos V, Ribera J M, Sarra J, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q – and 17p – ). Clin Cancer Res 2005; 11: 7757–7763
   PubMed Web of Science ®Google Scholar
• Ritgen M, Stilgenbauer S, Von Neuhoff N, Humpe A, Bruggemann M, Pott C, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602
   PubMed Web of Science ®Google Scholar
• Paneesha S, Milligan D W. Stem cell transplantation for chronic lymphocytic leukaemia. Br J Haematol 2005; 128: 145–152
   PubMed Web of Science ®Google Scholar
• Sorror M L, Maris M B, Sandmaier B M, Storer B E, Stuart M J, Hegenbart U, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–3829
   PubMed Web of Science ®Google Scholar
• Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How we treat refractory chronic lymphocytic leukemia. Blood 2006; 107: 1276–1283
   PubMed Web of Science ®Google Scholar
• Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029–1033
   PubMed Web of Science ®Google Scholar
• Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 2006; 107: 1724–1730
   PubMed Web of Science ®Google Scholar
• Milligan D W, Fernandes S, Dasgupta R, Davies F E, Matutes E, Fegan C D, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404
   PubMed Web of Science ®Google Scholar
• Gribben J G, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea E P, Fisher D C, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396
   PubMed Web of Science ®Google Scholar
• Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850–2858
   PubMed Web of Science ®Google Scholar
• Morrison V. The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 98–106
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 649–652
   PubMed Web of Science ®Google Scholar
• Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005; 130: 96–98
   PubMed Web of Science ®Google Scholar
• Morrison V A. Infections in patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemias2nd ed., B D Cheson. Marcel Dekker, New York 2001; 505–523
   Google Scholar
• Kyasa M J, Parrish R S, Schichman S A, Zent C S. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003; 74: 1–8
   PubMed Web of Science ®Google Scholar
• Diehl L, Ketchum L. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25(1)80–97
   PubMed Web of Science ®Google Scholar
• Giles F, O'Brien S, Keating M. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998; 25: 117–125
   PubMed Web of Science ®Google Scholar
• Kyasa M J, Hazlett L, Parrish R S, Schichman S A, Zent C S. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004; 45: 507–513
   PubMed Web of Science ®Google Scholar
• Hisada M, Biggar R, Greene M, Fraumeni J, Travis L. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–1981
   PubMed Web of Science ®Google Scholar